OGNOrganon & Co.
Pharmaceutical Preparations
- Revenue
- $6.2B
- 2.9% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $7.1B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear374% of net incomeCash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear13% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear31% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $6.3B | $6.2B | $6.3B | $6.4B | $6.2B | 2.9% |
| Net income | $1.4B | $917M | $1.0B | $864M | $187M | 78% |
| Operating cash flow | $2.2B | $858M | $799M | $939M | $700M | 25% |
| Capex | $192M | $196M | $251M | $175M | $162M | 7.4% |
| Stock-based comp | $59M | $75M | $101M | $105M | $77M | 27% |
| Dividends | $145M | $290M | $294M | $297M | $88M | 70% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 2368 | 15636 |
| FY2024 | — | — | 4805 | 12975 |
| FY2023 | — | — | 4371 | 12639 |
| FY2022 | — | — | 7965 | 12052 |
| FY2021 | — | — | 8372 | 11488 |